Mind Medicine Mindmed Inc (MNMD)

$12.10 +0.22 (1.85%)
Market Cap 1.19B
Revenue (ttm) 0.00
Net Income (ttm) -108.68M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.31
Volume 1,147,100
Avg Vol 2,022,422
Day's Range N/A - N/A
Shares Out 98.51M
Stochastic %K 87%
Beta 2.57
Analysts Strong Sell
Price Target $25.64

Company Profile

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is head...

Industry: Biotechnology
Sector: Healthcare
Phone: 212 220 6633
Address:
One World Trade Center, Suite 8500, New York, United States
BobbyCucumber
BobbyCucumber Nov. 28 at 2:49 PM
$MNMD
0 · Reply
BullsVSBearsVSYoMomma
BullsVSBearsVSYoMomma Nov. 28 at 2:41 PM
$MNMD
0 · Reply
dlawler_99
dlawler_99 Nov. 28 at 1:59 AM
$MNMD Happy Thanksgiving everyone, even Goral:)). Stay safe and joyful!
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Nov. 27 at 12:34 PM
Enter: $MNMD Calls Strike Price: $12 Expiry Date: DEC 19 2025 Buy in Price: $0.87 - $0.91 Sell Price: $1.64 Profit : +89% (Turn every $1 into $1.89) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
Woofofwallstreet69
Woofofwallstreet69 Nov. 26 at 3:47 PM
$MNMD should see gradual climb til Q2 2026 for anticipation of results from trials
1 · Reply
tskiba5
tskiba5 Nov. 26 at 2:51 PM
$MNMD several companies registering to import/manufacture psilocybin
1 · Reply
Iightning
Iightning Nov. 26 at 3:51 AM
1ightning® Options Trade Alert (Actionable) | Buy $MNMD Dec 19 $12 Call | Enter: $0.80 Exit: $1.21 | Profit: 51.20% ROI | https://1ightning.com
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Nov. 26 at 2:50 AM
Enter: $MNMD Calls Strike Price: $12 Expiry Date: DEC 19 2025 Buy in Price: $0.80 - $0.85 Sell Price: $1.30 Profit : +62% (Turn every $1 into $1.62) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
BankOnTheFuture
BankOnTheFuture Nov. 25 at 8:43 PM
$CMPS $ATAI $CYBN $MNMD
0 · Reply
blipper
blipper Nov. 25 at 3:09 PM
$MNMD hey king
0 · Reply
Latest News on MNMD
Mind Medicine (MindMed) Inc. (MNMD) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 9:46 PM EST - 21 days ago

Mind Medicine (MindMed) Inc. (MNMD) Q3 2025 Earnings Call Transcript

MindMed Reports Q3 2025 Financial Results and Business Updates

Nov 6, 2025, 4:01 PM EST - 21 days ago

MindMed Reports Q3 2025 Financial Results and Business Updates

MindMed to Participate in Upcoming Investor Conferences

Nov 5, 2025, 7:01 AM EST - 23 days ago

MindMed to Participate in Upcoming Investor Conferences

MindMed Announces New Employee Inducement Grant

Nov 3, 2025, 4:01 PM EST - 24 days ago

MindMed Announces New Employee Inducement Grant

Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

Nov 3, 2025, 7:01 AM EST - 25 days ago

Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

MindMed to Report Q3 2025 Financial Results on November 6, 2025

Oct 30, 2025, 4:01 PM EDT - 4 weeks ago

MindMed to Report Q3 2025 Financial Results on November 6, 2025

Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering

Oct 29, 2025, 10:14 PM EDT - 4 weeks ago

Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering

Mind Medicine (MindMed) Inc. Announces Proposed Public Offering

Oct 29, 2025, 4:01 PM EDT - 4 weeks ago

Mind Medicine (MindMed) Inc. Announces Proposed Public Offering

MindMed Nears Pivotal Year: Strong Fundamentals Make It A Buy

Oct 14, 2025, 12:28 PM EDT - 6 weeks ago

MindMed Nears Pivotal Year: Strong Fundamentals Make It A Buy

Mind Medicine Analyst Cites Strong Phase 3 Pipeline For Anxiety, Depression

Oct 13, 2025, 2:54 PM EDT - 6 weeks ago

Mind Medicine Analyst Cites Strong Phase 3 Pipeline For Anxiety, Depression

MindMed Announces New Employee Inducement Grants

Sep 22, 2025, 4:01 PM EDT - 2 months ago

MindMed Announces New Employee Inducement Grants

New MindMed Retrospective Study Presented at Psych Congress 2025 Reveals High Rates of Suicidal Ideation (SI) in Adults with Generalized Anxiety Disorder (GAD)

Sep 19, 2025, 7:00 AM EDT - 2 months ago

New MindMed Retrospective Study Presented at Psych Congress 2025 Reveals High Rates of Suicidal Ideation (SI) in Adults with Generalized Anxiety Disorder (GAD)

Journal of the American Medical Association (JAMA) Publishes Results from First-Ever Randomized, Placebo-Controlled Clinical Trial Assessing the Dose-Dependent Efficacy of MM120 (Lysergide D-Tartrate, LSD) in Generalized Anxiety Disorder (GAD)

Sep 4, 2025, 11:05 AM EDT - 3 months ago

Journal of the American Medical Association (JAMA) Publishes Results from First-Ever Randomized, Placebo-Controlled Clinical Trial Assessing the Dose-Dependent Efficacy of MM120 (Lysergide D-Tartrate, LSD) in Generalized Anxiety Disorder (GAD)

MindMed to Participate in September Investor Conferences

Aug 28, 2025, 7:00 AM EDT - 3 months ago

MindMed to Participate in September Investor Conferences

If You'd Invested $1,000 in Mind Medicine (MNMD) Stock 5 Years Ago, Here's How Much You'd Have Today

Aug 12, 2025, 3:43 AM EDT - 3 months ago

If You'd Invested $1,000 in Mind Medicine (MNMD) Stock 5 Years Ago, Here's How Much You'd Have Today

1 Reason to Buy MindMed (MNMD)

Aug 7, 2025, 5:25 AM EDT - 4 months ago

1 Reason to Buy MindMed (MNMD)

MindMed (MNMD) Q2 Net Loss Jumps 625%

Aug 1, 2025, 6:43 PM EDT - 4 months ago

MindMed (MNMD) Q2 Net Loss Jumps 625%

Mind Medicine (MindMed) Inc. (MNMD) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 9:48 PM EDT - 4 months ago

Mind Medicine (MindMed) Inc. (MNMD) Q2 2025 Earnings Call Transcript

MindMed Reports Q2 2025 Financial Results and Business Updates

Jul 31, 2025, 4:01 PM EDT - 4 months ago

MindMed Reports Q2 2025 Financial Results and Business Updates

MindMed to Report Second Quarter 2025 Financial Results on July 31, 2025

Jul 24, 2025, 7:00 AM EDT - 4 months ago

MindMed to Report Second Quarter 2025 Financial Results on July 31, 2025

Why Mind Medicine Gave Investors a Powerful Buzz in May

Jun 4, 2025, 7:02 AM EDT - 6 months ago

Why Mind Medicine Gave Investors a Powerful Buzz in May

MindMed to Participate in June Investor Conferences

May 28, 2025, 7:00 AM EDT - 6 months ago

MindMed to Participate in June Investor Conferences

MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer

May 27, 2025, 7:00 AM EDT - 6 months ago

MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer

Why Mind Medicine Stock Vaulted More Than 8% Higher Today

May 20, 2025, 5:33 PM EDT - 6 months ago

Why Mind Medicine Stock Vaulted More Than 8% Higher Today

MindMed to Present at the 2025 RBC Capital Markets Global Healthcare Conference

May 13, 2025, 7:00 AM EDT - 7 months ago

MindMed to Present at the 2025 RBC Capital Markets Global Healthcare Conference

Mind Medicine (MindMed) Inc. (MNMD) Q1 2025 Earnings Call Transcript

May 8, 2025, 9:55 AM EDT - 7 months ago

Mind Medicine (MindMed) Inc. (MNMD) Q1 2025 Earnings Call Transcript

MindMed Reports First Quarter 2025 Financial Results and Recent Business Updates

May 8, 2025, 7:00 AM EDT - 7 months ago

MindMed Reports First Quarter 2025 Financial Results and Recent Business Updates

MindMed to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 24, 2025, 7:00 AM EDT - 7 months ago

MindMed to Report First Quarter 2025 Financial Results on May 8, 2025

MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD)

Apr 15, 2025, 7:00 AM EDT - 8 months ago

MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD)

MindMed Appoints Matt Wiley as Chief Commercial Officer

Mar 17, 2025, 7:00 AM EDT - 9 months ago

MindMed Appoints Matt Wiley as Chief Commercial Officer

Mind Medicine (MindMed) Inc. (MNMD) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 12:10 PM EST - 9 months ago

Mind Medicine (MindMed) Inc. (MNMD) Q4 2024 Earnings Call Transcript

MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates

Mar 6, 2025, 7:00 AM EST - 9 months ago

MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates

MindMed to Present at Leerink's Global Healthcare Conference 2025

Mar 4, 2025, 7:00 AM EST - 9 months ago

MindMed to Present at Leerink's Global Healthcare Conference 2025

MindMed to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

Feb 20, 2025, 7:00 AM EST - 10 months ago

MindMed to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

Why Mind Medicine Stock Is Skyrocketing Today

Feb 14, 2025, 3:35 PM EST - 10 months ago

Why Mind Medicine Stock Is Skyrocketing Today

MindMed to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 7:00 AM EST - 10 months ago

MindMed to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder

Jan 30, 2025, 7:00 AM EST - 10 months ago

MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder

Why Mind Medicine Stock Is Soaring Today

Jan 7, 2025, 2:25 PM EST - 11 months ago

Why Mind Medicine Stock Is Soaring Today

MindMed to Be Added to the Nasdaq Biotechnology Index

Dec 19, 2024, 7:00 AM EST - 1 year ago

MindMed to Be Added to the Nasdaq Biotechnology Index

MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)

Dec 16, 2024, 7:00 AM EST - 1 year ago

MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)

MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress

Dec 11, 2024, 7:00 AM EST - 1 year ago

MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress

MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)

Dec 5, 2024, 7:00 AM EST - 1 year ago

MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)

MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy

Dec 3, 2024, 7:00 AM EST - 1 year ago

MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy

MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer

Nov 18, 2024, 7:00 AM EST - 1 year ago

MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer

Mind Medicine: No News = Good News

Nov 10, 2024, 9:55 AM EST - 1 year ago

Mind Medicine: No News = Good News

Mind Medicine (MindMed) Inc. (MNMD) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 8:06 PM EST - 1 year ago

Mind Medicine (MindMed) Inc. (MNMD) Q3 2024 Earnings Call Transcript

MindMed Reports Third Quarter 2024 Financial Results and Business Updates

Nov 7, 2024, 4:01 PM EST - 1 year ago

MindMed Reports Third Quarter 2024 Financial Results and Business Updates

Mind Medicine: Two Pathways Created From One Pipeline Clinical Candidate

Nov 4, 2024, 4:04 PM EST - 1 year ago

Mind Medicine: Two Pathways Created From One Pipeline Clinical Candidate

MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2024 Financial Results and Provide Business Update

Oct 24, 2024, 7:00 AM EDT - 1 year ago

MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2024 Financial Results and Provide Business Update

Psychedelic Stocks: Focus On Their Cash

Aug 15, 2024, 12:30 PM EDT - 1 year ago

Psychedelic Stocks: Focus On Their Cash

CMPS

BobbyCucumber
BobbyCucumber Nov. 28 at 2:49 PM
$MNMD
0 · Reply
BullsVSBearsVSYoMomma
BullsVSBearsVSYoMomma Nov. 28 at 2:41 PM
$MNMD
0 · Reply
dlawler_99
dlawler_99 Nov. 28 at 1:59 AM
$MNMD Happy Thanksgiving everyone, even Goral:)). Stay safe and joyful!
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Nov. 27 at 12:34 PM
Enter: $MNMD Calls Strike Price: $12 Expiry Date: DEC 19 2025 Buy in Price: $0.87 - $0.91 Sell Price: $1.64 Profit : +89% (Turn every $1 into $1.89) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
Woofofwallstreet69
Woofofwallstreet69 Nov. 26 at 3:47 PM
$MNMD should see gradual climb til Q2 2026 for anticipation of results from trials
1 · Reply
tskiba5
tskiba5 Nov. 26 at 2:51 PM
$MNMD several companies registering to import/manufacture psilocybin
1 · Reply
Iightning
Iightning Nov. 26 at 3:51 AM
1ightning® Options Trade Alert (Actionable) | Buy $MNMD Dec 19 $12 Call | Enter: $0.80 Exit: $1.21 | Profit: 51.20% ROI | https://1ightning.com
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Nov. 26 at 2:50 AM
Enter: $MNMD Calls Strike Price: $12 Expiry Date: DEC 19 2025 Buy in Price: $0.80 - $0.85 Sell Price: $1.30 Profit : +62% (Turn every $1 into $1.62) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
BankOnTheFuture
BankOnTheFuture Nov. 25 at 8:43 PM
$CMPS $ATAI $CYBN $MNMD
0 · Reply
blipper
blipper Nov. 25 at 3:09 PM
$MNMD hey king
0 · Reply
Iightning
Iightning Nov. 25 at 1:57 PM
1ightning® Options Trade Alert (Actionable) | Buy $MNMD Dec 19 $12 Call | Enter: $0.80 Exit: $1.21 | Profit: 51.20% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 25 at 2:49 AM
1ightning® Options Trade Alert (Actionable) | Buy $MNMD Dec 19 $12 Call | Enter: $0.80 Exit: $1.21 | Profit: 51.20% ROI | https://1ightning.com
0 · Reply
dsfwf
dsfwf Nov. 25 at 12:01 AM
$MNMD closed at $11.87 (+10.02%), showing strong momentum with increasing volume.If it can hold above 11.5, it may continue pushing toward the previous high of $14.43.THE trend is looking bullish worth keeping an eye on
0 · Reply
BullsVSBearsVSYoMomma
BullsVSBearsVSYoMomma Nov. 24 at 10:12 PM
$MNMD Gap up filled now. Run it
2 · Reply
zcurrency
zcurrency Nov. 24 at 9:47 PM
$MNMD https://x.com/mindmedco/status/1992969954748969153?s=46&t=lLi_3TjkIo8AfK12UxM3Vg
0 · Reply
dlawler_99
dlawler_99 Nov. 24 at 8:56 PM
$MNMD
0 · Reply
dlawler_99
dlawler_99 Nov. 24 at 8:56 PM
$MNMD resistance is now support🤯
0 · Reply
Tradetime3472
Tradetime3472 Nov. 24 at 8:28 PM
$ATAI $CMPS $CYBN $MNMD and $PBM is the only Nasdaq listed company that has ibogaine operations straight from the source in Africa. Most likely will get a part of the $50M Texas ibogain fund
3 · Reply
twiggs462
twiggs462 Nov. 24 at 7:09 PM
$MNMD Quietly filling the PSILOs - Understanding - FORMULATIONS OF PSILOCIN THAT HAVE ENHANCED STABILITY Patent Application (20250205196) THIS IS BIG.... Read more here: https://www.reddit.com/r/MindMedInvestorsClub/comments/1p5pz9x/quietly_filling_the_psilos_understanding/
2 · Reply
DEADSTOCKSTRADER
DEADSTOCKSTRADER Nov. 24 at 7:08 PM
$MNMD $SPY $QQQ
0 · Reply
dlawler_99
dlawler_99 Nov. 24 at 7:06 PM
$MNMD $11.74 resistance
0 · Reply
DARKP00L
DARKP00L Nov. 24 at 6:48 PM
$MNMD this stock is seeing a surge in interest. Market volatility might ensue!
0 · Reply